Seismic Therapeutic Selected as an Endpoints 11 Most Promising Biotech Startup

Cambridge, Mass., September 21, 2023 – Seismic Therapeutic, Inc., the machine learning immunology company, today announced that it has been named as one of the Endpoints 11 most promising private biotechnology companies of 2023. Seismic has been chosen by the Endpoints News editorial team because of the company’s strengths in science, leadership, financial backers and opportunity to move the dial on the development of new medicines for patients with autoimmune diseases.

“We are honored to be recognized as an Endpoints 11 company, and this serves as a testament to the hard work and dedication of our entire team,” said Jo Viney, PhD, Co-Founder, President and CEO of Seismic Therapeutic. “This recognition further energizes our Seismonauts to strive to make an impact in the biotechnology industry and in our communities. We believe that by applying machine learning to immunology biologics drug discovery we are paving the way to creating positive change in the autoimmune landscape and the lives of patients.”

The 2023 Endpoints 11 winners were announced at an awards gala held at the State Room in Boston on Wednesday, September 20, 2023.

With the company’s innovative IMPACT platform integrating machine learning with biologics drug discovery, Seismic is building a pipeline of novel enzymes and antibodies to address unmet medical needs for diseases involving humoral immunity and cell-mediated immunity, the two arms of the adaptive immune system. Within 18 months since launching, Seismic’s two lead drug programs are in IND-enabling studies, each with potential to improve the treatment landscape in autoimmune diseases:

• Seismic is discovering and developing multiple types of immunoglobulin sculpting (IgSc) enzyme therapeutics that modify different pathogenic immunoglobulins . Its lead IgSc program is a novel engineered pan-IgG protease, suitable for the treatment of acute and chronic autoantibody mediated diseases.
• Seismic is discovering and developing Dual-cell Bidirectional (DcB) antibody therapies that target dysregulated cell-mediated immunity by optimally engaging both T cells and antigen presenting cells, such as B cells, to restore homeostasis. Its lead DcB antibody program agonizes PD-1, a well-known inhibitory checkpoint receptor on T cells, and selectively engages the inhibitory Fc gamma receptor, FcγRIIb, on B cells and other antigen-presenting cells.

About Seismic Therapeutic
Seismic Therapeutic™ is a biotechnology company making a major shift in how immunology therapies are discovered and developed, enabled by machine learning. The company has a growing preclinical stage best-in-class and first-in-class biologics pipeline, derived from its integrated IMPACT platform, to control dysregulated adaptive immunity and address multiple autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow us on LinkedIn and on X (formerly Twitter) @Seismic_Tx.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com